2024 Prediction from Greg Baker
Greg Baker is the CEO of AffirmedRx. He predicts that "transparent PBMs will gain traction" in 2024.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Greg Baker said:
“In 2024, Optum Rx will follow suit with their own group purchasing organization (GPO) spinoff so they can take advantage of acquisition price models like CVS’ Averon and Express Scripts’
ClearNetwork. Several media outlets have compared these programs to the Mark Cuban Cost Plus Drug Company, but unlike Cost Plus, which fully discloses what it pays for medications, none of these GPOs will take a similar stance on disclosure.
Transparent PBMs will continue to gain traction in the market as traditional PBMs continue to lead employers to higher-cost, opaque models. Employers are told each year that their drug discounts will get better and their rebates will improve and yet every year their overall costs continue to increase.
Plan sponsors pharmaceutical costs will increase in 2024 and profits associated with companies that own traditional PBMs will see profit increases across all of their affiliate organizations.”
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Healthcare journalist, HIV advocate and educator Juan Michael Porter II discussed moderating the "Future of Science" session at the International AIDS Society's AIDS 2024 meeting in Munich, Germany, as well as addressing "founder's syndrome" in AIDS organizations and the inclusivity of the event.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
